Burosumab: A new drug to treat hypophosphatemic rickets.

Article Details

Citation

Copy to clipboard

Kutilek S

Burosumab: A new drug to treat hypophosphatemic rickets.

Sudan J Paediatr. 2017;17(2):71-73. doi: 10.24911/SJP.2017.2.11.

PubMed ID

29545670 [ View in PubMed

]

Abstract

Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on burosumab therapy.

DrugBank Data that Cites this Article

Drugs

Burosumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Burosumab	Fibroblast growth factor 23	Protein	Humans	Yes	Antagonist	Details